Vertex Pharmaceuticals Becomes #232 Most Shorted S&P 500 Component, Replacing Exxon Mobil

The most recent short interest data has been released by the NASDAQ for the 06/15/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

START SLIDESHOW:
Top 25 S.A.F.E. Dividend Stocks »

In our new rank based on the most recent short interest data from NASDAQ, Vertex Pharmaceuticals, Inc. ( VRTX) has taken over the position of #232 most shorted S&P 500 component, from Exxon Mobil Corp. ( XOM) which is now in the #253 spot. The "days to cover" at 06/15/2015 was 3.93 for VRTX, and 3.71 for XOM; this compares to the average across all S&P 500 components of 4.78 (up from the average back on the 05/29/2015 settlement date of 4.41). The chart below shows the movement over time of the "days to cover" values of both VRTX and XOM, versus the average S&P 500 component.

Loading+chart++2015+TickerTech.com

Below is a chart showing the relative positions of VRTX versus XOM over time within the 500 S&P 500 components, with #1 representing the component with the highest "days to cover" value (most heavily shorted) and #500 representing the component with the lowest "days to cover" value (least heavily shorted):

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants